Home LiteratureArticle Details
PMID: 1098809 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S. Review

The status of cardiac transplantation, 1975.

Circulation ·Vol. 52 ·No. 4 ·1975-10-00 ·Pages 531-9

Rider AK, Copeland JG, Hunt SA, Mason J, Specter MJ, Winkle RA, Bieber CP, Billingham ME, Dong E, Griepp RB, Schroeder JS, Stinson EB, Harrison DC, Shumway NE

Abstract

Since December 1967, 263 human cardiac transplant operations have been performed throughout the world. Eighty-two of these were performed at Stanford University Medical Center, In 1974, 27 such operations were performed, 15 at Stanford Survival rates for the entire Standford series are 48% at one year and 25% at three years; survival rates at one and three years for patients surviving the first three critical months after transplantation are 77% and 42%, respectively. Recipients under the age of 55 years, with New York Heart Association Class IV cardiac disability, are selected for transplant procedures according to criteria dictated by experience over the past seven years. A routine immunsuppressive regimen for organ transplantation, incorporating prednisone, azathioprine, and antithymocyte globulin is employed early postoperatively, and prednisone and azathioprine are used for indefinite maintenance therapy. Acute cardiac graft rejection in nearly all recipients is diagnosed by clinical signs, electrocardiographic changes, and percutaneous transvenous endomyocardial biopsy. Ninety-five percent of acute rejection episodes are reversible with appropriate immunosuppressive treatment, but infectious complications are common and have accounted for 56% of all postoperative deaths. The Stanford experience in cardiac transplantation has demonstrated the potential therapeutic value of this procedure. Maximum survival now extends beyond five years. Satisfactory graft function has been documented in long-term surviving patients, the majority of whom have enjoyed a high degree of social and physical rehabilitation.

MeSH Terms
Acute Disease Adolescent Adult Antilymphocyte Serum/therapeutic use Cardiac Surgical Procedures/mortality Child Coronary Disease/surgery Graft Rejection/diagnosis,drug therapy Heart/physiology Heart Transplantation Histocompatibility Testing Humans Immunosuppression Therapy Methylprednisolone/therapeutic use Middle Aged Myocardium/pathology Postoperative Care Postoperative Complications Rehabilitation T-Lymphocytes/immunology Tissue Donors Transplantation, Homologous/methods,mortality
Chemicals
Antilymphocyte Serum Methylprednisolone
Authors & Affiliations
14 authors, click to expand affiliations / ORCID
Rider A K
Copeland J G
Hunt S A
Mason J
Specter M J
Winkle R A
Bieber C P
Billingham M E
Dong E
Griepp R B
Schroeder J S
Stinson E B
Harrison D C
Shumway N E
Article Info
Journal
Circulation
Abbr.
Circulation
ISSN
0009-7322
Published
1975-10-00
Pages
531-9
Language
English
Region
United States
NLM ID
0147763
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com